This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)

2024-511503-41-00 Protocol 1403-0001 Human pharmacology (Phase I) - Other Ended

Start 13 Aug 2021 · End 14 Nov 2025 · Status Ended · 6 EU/EEA countries · 14 sites · Protocol 1403-0001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 261
Countries 6
Sites 14

Advanced or metastatic solid tumors

Key facts

Sponsor
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
13 Aug 2021 → 14 Nov 2025
Decision date (initial)
2024-09-26
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-511503-41-00
EudraCT number
2017-003210-95
WHO UTN
U1111-1305-3046

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced or metastatic solid tumors

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Boehringer Ingelheim Espana S.A.

Sponsor organisation
Boehringer Ingelheim Espana S.A.
Address
Carrer Prat De La Riba 50, Sant Cugat Del Valles Sant Cugat Del Valles
City
Barcelona
Postcode
08174
Country
Spain

Locations

6 EU/EEA countries · 14 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 22 2
Denmark Ended 9 1
Germany Ended 29 4
Poland Ended 20 2
Spain Ended 24 4
Sweden Ended 8 1
Rest of world
Canada, Israel, Korea, Republic of, United States, Japan
149

Investigational sites

Belgium

2 sites · Ended
UZ Leuven
Medical Oncology, Herestraat 49, 3000, Leuven
Cliniques Universitaires Saint-Luc
Unité d'Oncologie Médicale, Hippokrateslaan 10, Batiment 54, Sint-Lambrechts-Woluwe

Denmark

1 site · Ended
Rigshospitalet
Department of Oncology, Blegdamsvej 9, 2100, Copenhagen Oe

Germany

4 sites · Ended
Universitaetsklinikum Tuebingen AöR
Abteilung Innere Medizin VIII, Otfried-Mueller-Strasse 10, Nordstadt, Tuebingen
University Hospital Cologne AöR
Klinik I für Innere Medizin, Kerpener Strasse 62, Lindenthal, Cologne
HELIOS Klinikum Berlin-Buch GmbH
Onkologie und Palliativmedizin, Schwanebecker Chaussee 50, Buch, Berlin
Universitaetsmedizin Goettingen
Klinik für Hämatologie und Medizinische Onkologie, Robert-Koch-Strasse 40, Weende, Goettingen

Poland

2 sites · Ended
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
The Early-Phase Clinical Trials Unit, Ul. Wilhelma Konrada Roentgena 5, 02-781, Warsaw
Med Polonia Sp. z o.o.
Limited liability company, Obornicka 262, 60-693, Poznan

Spain

4 sites · Ended
Complexo Hospitalario Universitario De Santiago
Servicio de Oncología Médica, Calle Choupana Da S/n, 15706, Santiago De Compostela
Hospital Universitario Fundacion Jimenez Diaz
Servicio de Oncología Médica, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Clinic De Barcelona
Clinical Trials Unit, Calle Villarroel 170, 08036, Barcelona
Hospital Universitari Vall D Hebron
Servicio de Oncología Médica, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona

Sweden

1 site · Ended
Karolinska University Hospital
Department of Clinical Cancer Studies|Cancer Theme|Karolinska University Hospital, Eugeniavagen 3, 171 64, Solna

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2021-08-13 2025-06-26 2021-08-26 2024-09-23
Denmark 2023-06-27 2025-08-28 2023-08-07 2024-09-23
Germany 2021-08-25 2025-07-29 2021-11-15 2024-09-23
Poland 2022-02-22 2025-11-13 2022-05-09 2024-09-23
Spain 2021-10-14 2025-07-22 2022-04-06 2024-09-23
Sweden 2023-03-07 2025-07-29 2023-03-21 2024-09-23

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-28 Spain Acceptable with conditions
2024-09-26
2024-09-26
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-12-09 Spain Acceptable with conditions
2024-09-26
2024-12-09
3 SUBSTANTIAL MODIFICATION SM-1 2025-02-28 Spain Acceptable
2025-05-23
2025-05-23
4 SUBSTANTIAL MODIFICATION SM-2 2025-06-17 Acceptable 2025-06-20
5 NON SUBSTANTIAL MODIFICATION NSM-2 2025-07-23 Spain Acceptable 2025-07-23